Published on March 12, 2014
Cancer-Code Corporation The dawn of a new approach to cancer treatment
The unfortunate realities of cancer New cancer cases will jump to 22 million cases annually in the next two decades -USA Today, Feb. 4, 2014 It is well known that chemotherapy and radiation treatments cause sickness, pain, disﬁgurement, depression, spread of the cancer, baldness, and are often ineffective.
Cancer-Code Corporation (C³) ! A bioelectronic medical approach to cancer treatment C³ expects to determine the electrical codes for lung, prostate and breast cancers during an initial Phase 1 six (6) month demonstration period and many additional cancers during a follow-on six (6) months.
! C³ intends to establish itself as the leading champion for the newly emerging ﬁeld of cancer cell communication signaling medicine in its dynamic quest to reduce the cancer death rate and improve the survival rate, while lowering the cost of cancer treatments and medical therapy. C³ is seeking funding for initial animal studies and commercialization efforts The Objectives
The Technology • The application of ultra-low voltage signals to target cancer cells and trigger and cause cellular suicide (apoptosis). • The treatment signals are very tiny and mimic the power levels found naturally in cancerous cells. • No chemotherapy or radiation is used • The technology takes advantage of the fact that the malignant cells in the tumor are linked together and thus, will spread the signals within the tumor. • C³'s effort is to demonstrate the rapid killing of human breast, prostate and lung cancer cells, which are implanted on the backs of laboratory rodents and commercialize products based on our studies. • Pathology examinations or evaluations will scientiﬁcally verify the results of our approach.
Business Model • C³ is a for-proﬁt corporation and will commercialize or license commercial rights to manufacture and market C³ products (initially a hybrid computerized neuro-electric technology platform about the size of a domino, conﬁgured with treatment codes and ancillary products) to kill selected cancers. • C³ would expect revenues/royalties income from this ultra-low voltage commercial product line, which would evolve from such arrangement. • The marketable products would be compact in size and offered to hospitals, cancer research institutes, university medical schools and treatment facilities and veterinarian hospitals or veterinarians. • There is no known competitive medical technology; not even close!
U.S. Patent No. 8,656,930 - “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy,” ! U.S. Patent No. 8,315,712 - “Hybrid Scientiﬁc Computer System for Processing Cancer Cell Signals as Medical Therapy” ! U.S. Patent Application Serial No. 12/334,212 - “Method to Switch-Off Cancer Cell Electrical Communication Codes as Medical Therapy”. ! U.S. Patent Application Serial No. 12/936,778 - “System and Method to Elicit Apoptosis in Malignant Tumor Cells for Medical Therapy”. ! U.S. Patent Application Serial No. 14/182,417 - “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy” ! U.S. Provisional Application ﬁled February 14, 2014 - “Encoded Bioelectronic Method and System for Slaying Cancer by Rapid Triggering of Cellular Apoptosis and Karyorrhexis” [Patent title edited for confidentiality] Intellectual Property Additional patents will be ﬁled in 2014 including priority for new foreign rights
Competitive Landscape Noteworthy - GSK (GlaxoSmithKline) - announced in 2013 an unprecedented effort to develop bioelectronics as the “medicine of the future”. GSK, which is Britain’s largest drug maker, hopes to have the ﬁrst medicine that “speaks the electrical language of the [human] body ready for approval by 2020”. What GSK lacks, however, is the intellectual property rights in this area, particularly in the ﬁeld of bioelectronic medicines for cancer treatment. C³ is currently the only licensee with rights to develop and commercialize the IP
117 Bryn Mawr Dr SE Albuquerque, NM 87106 info@cancercodecorp cancercodecorp.com 505-314-1311 or 505-314-1312
Calcification Inhibitors in CKD and Dialysis Patients
Cancer-Code Corporation, ... The basis of C³ approach/technology emerged from many ... Scientists are trying out new electronic devices to treat ...
Cancer-Code Corporation, Albuquerque, NM. 397 likes · 2 were here. The basis of C³ approach/technology emerged from many years of exhaustive studies and...
Cancer-Code Corporation announces the issuance of U.S. Patent No. 8,656,930: "Method and System for Processing Cancer Cell Electrical Signals for Medical ...
Cancer-Code Corporation ... (PRWEB) February 26, 2014 Cancer-Code ... and represents the dawn of an entirely new approach to cancer treatment ...
Cancer-Code Corporation ... 'Electroceutical' Targeted Cancer Therapy To ... and represents the dawn of an entirely new approach to cancer treatment. ...
U.S. Patent issued for Cancer-Code Corporation ... approaches of treatment, and represents the dawn of an entirely new approach to cancer treatment. ...
CA: A Cancer Journal for ... Whether these recommendations will gain traction in the prostate cancer treatment ... New lung cancer screening guidelines ...
John Crown: Move aside bureaucrats and let us take a lead. ... A breast cancer specialist, ... “It was only when a new minister of health, ...